Literature DB >> 18001771

S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study.

Johann Steiner1, Hans-Gert Bernstein, Hendrik Bielau, Nadine Farkas, Jana Winter, Henrik Dobrowolny, Ralf Brisch, Tomasz Gos, Christian Mawrin, Aye Mu Myint, Bernhard Bogerts.   

Abstract

OBJECTIVE: Several studies have revealed increased S100B levels in peripheral blood and cerebrospinal fluid (CSF) of patients with schizophrenia. In this context, it was postulated that elevated levels of S100B may indicate changes of pathophysiological significance to brain tissue in general and astrocytes in particular. However, no histological study has been published on the cellular distribution of S100B in the brain of individuals with schizophrenia to clarify this hypothesis.
METHODS: The cell-density of S100B-immunopositive glia was analyzed in the anterior cingulate, dorsolateral prefrontal (DLPF), orbitofrontal, and superior temporal cortices/adjacent white matter, pyramidal layer/alveus of the hippocampus, and the mediodorsal thalamic nucleus of 18 patients with schizophrenia and 16 matched control subjects.
RESULTS: Cortical brain regions contained more S100B-immunopositive glia in the schizophrenia group relative to controls (P=0.046). This effect was caused by the paranoid schizophrenia subgroup (P=0.018). Separate analysis of white matter revealed no diagnostic main group effect (P=0.846). However, the white matter of patients with paranoid schizophrenia contained more (mainly oligodendrocytic) S100B-positive glia as compared to residual schizophrenia (P=0.021). These effects were particularly pronounced in the DLPF brain area.
CONCLUSION: Our study reveals distinct histological patterns of S100B immunoeactive glia in two schizophrenia subtypes. This may be indicative of a heterogenic pathophysiology or distinct compensatory abilities: Astro-/oligodendroglial activation may result in increased cellular S100B in paranoid schizophrenia. On the contrary, residual schizophrenia may be caused by white matter oligodendroglial damage or dysfunction, associated with a release of S100B into body fluids.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18001771     DOI: 10.1016/j.jpsychires.2007.10.001

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  33 in total

1.  Reduced density of hypothalamic VGF-immunoreactive neurons in schizophrenia: a potential link to impaired growth factor signaling and energy homeostasis.

Authors:  Stefan Busse; Hans-Gert Bernstein; Mandy Busse; Hendrik Bielau; Ralf Brisch; Christian Mawrin; Susan Müller; Zoltán Sarnyai; Tomasz Gos; Bernhard Bogerts; Johann Steiner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-14       Impact factor: 5.270

2.  Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia.

Authors:  Pavel Katsel; William Byne; Panos Roussos; Weilun Tan; Larry Siever; Vahram Haroutunian
Journal:  Neuropsychopharmacology       Date:  2011-01-26       Impact factor: 7.853

3.  Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Ikwunga Wonodi; Rosalinda C Roberts; Arash Rassoulpour; Robert P McMahon; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2010-10-29       Impact factor: 9.306

Review 4.  Searching for neuropathology: gliosis in schizophrenia.

Authors:  Tatiana P Schnieder; Andrew J Dwork
Journal:  Biol Psychiatry       Date:  2010-10-30       Impact factor: 13.382

5.  Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia.

Authors:  Huiqiong Deng; Ramandeep S Kahlon; Satyajit Mohite; Pooja A Amin; Giovana Zunta-Soares; Gabriela D Colpo; Laura Stertz; Gabriel R Fries; Consuelo Walss-Bass; Jair C Soares; Olaoluwa O Okusaga
Journal:  Psychiatr Q       Date:  2018-03

6.  Neuropathological changes in the nucleus basalis in schizophrenia.

Authors:  M R Williams; R Marsh; C D Macdonald; J Jain; R K B Pearce; S R Hirsch; O Ansorge; S M Gentleman; M Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-12-11       Impact factor: 5.270

7.  Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism--effects of medication.

Authors:  Robert D Oades; Maria R Dauvermann; Benno G Schimmelmann; Markus J Schwarz; Aye-Mu Myint
Journal:  Behav Brain Funct       Date:  2010-05-28       Impact factor: 3.759

8.  S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin Resistance.

Authors:  Johann Steiner; Aye Mu Myint; Kolja Schiltz; Sabine Westphal; Hans-Gert Bernstein; Martin Walter; Matthias L Schroeter; Markus J Schwarz; Bernhard Bogerts
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-06-10

9.  S100B Protein, A Damage-Associated Molecular Pattern Protein in the Brain and Heart, and Beyond.

Authors:  Guglielmo Sorci; Roberta Bianchi; Francesca Riuzzi; Claudia Tubaro; Cataldo Arcuri; Ileana Giambanco; Rosario Donato
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-08-18

10.  Breaching the blood-brain barrier as a gate to psychiatric disorder.

Authors:  Hadar Shalev; Yonatan Serlin; Alon Friedman
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.